By employing an integrative approach that combines network pharmacology with in vivo pharmacological studies targeting p38MAPK inhibition, we have identified and confirmed the pivotal regulatory function of the VEGF/p38MAPK/HSP27 signaling axis in CRC associated pro-tumor inflammation. This evidence concerns the gene HSPB1 and neoplasm.